Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

107 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Vectors for glucose-dependent protein expression in Saccharomyces cerevisiae.
Thierfelder S, Ostermann K, Göbel A, Rödel G. Thierfelder S, et al. Appl Biochem Biotechnol. 2011 Apr;163(8):954-64. doi: 10.1007/s12010-010-9099-5. Epub 2010 Oct 15. Appl Biochem Biotechnol. 2011. PMID: 20949330
(Gene 156, 119-122, 1995), we have generated a set of plasmids that allow the glucose-dependent expression of target genes in the yeast, Saccharomyces cerevisiae. ...Fluorescence is induced 2.7-fold using the HXK1, 2.3-fold using the YGR243-, 5-fold using the HXT7- and 12. …
(Gene 156, 119-122, 1995), we have generated a set of plasmids that allow the glucose-dependent expression of target genes in the yea …
The social status of the male Nile tilapia (Oreochromis niloticus) influences testis structure and gene expression.
Pfennig F, Kurth T, Meissner S, Standke A, Hoppe M, Zieschang F, Reitmayer C, Göbel A, Kretzschmar G, Gutzeit HO. Pfennig F, et al. Reproduction. 2012 Jan 1;143(1):71-84. doi: 10.1530/REP-11-0292. Epub 2011 Oct 26. Reproduction. 2012. PMID: 22031714
The Nile tilapia is a promising model to study social cues and gonadotropic signals on testis development in vertebrates....
The Nile tilapia is a promising model to study social cues and gonadotropic signals on testis development in vertebrates....
Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
Göbel A, Browne AJ, Thiele S, Rauner M, Hofbauer LC, Rachner TD. Göbel A, et al. Breast Cancer Res Treat. 2015 Dec;154(3):623-31. doi: 10.1007/s10549-015-3624-8. Epub 2015 Oct 29. Breast Cancer Res Treat. 2015. PMID: 26515701
We show that a sequential mevalonate pathway blockade using statins and amino-bisphosphonates suppresses DKK-1 more significantly than the individual agents alone. ...Hence our study reveals that a sequential mevalonate pathway blockade allows for the combined use o …
We show that a sequential mevalonate pathway blockade using statins and amino-bisphosphonates suppresses DKK-1 more significantly tha …
Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
Rachner TD, Göbel A, Thiele S, Rauner M, Benad-Mehner P, Hadji P, Bauer T, Muders MH, Baretton GB, Jakob F, Ebert R, Bornhäuser M, Schem C, Hofbauer LC. Rachner TD, et al. Breast Cancer Res. 2014 Feb 14;16(1):R20. doi: 10.1186/bcr3616. Breast Cancer Res. 2014. PMID: 24528599 Free PMC article.
In line with the in vitro data, treatment of breast cancer patients with zoledronic acid decreased DKK-1 levels by a mean of 60% after 12 months of treatment. CONCLUSION: DKK-1 is a novel target of the mevalonate pathway that is suppressed by zoledronic acid and ato …
In line with the in vitro data, treatment of breast cancer patients with zoledronic acid decreased DKK-1 levels by a mean of 60% afte …
Regulation of VEGF by mevalonate pathway inhibition in breast cancer.
Rachner TD, Göbel A, Junker M, Hötzel J, Benad-Mehner P, Hadji P, Hofbauer LC. Rachner TD, et al. J Bone Oncol. 2013 Jun 7;2(3):110-5. doi: 10.1016/j.jbo.2013.05.003. eCollection 2013 Sep. J Bone Oncol. 2013. PMID: 26909280 Free PMC article.
In contrast to our in vitro findings, VEGF serum levels decreased in all patients after 6-9 months of treatment (by an average of 41%) as assessed in a small pilot trial. ...The increases of VEGF in the cancer cells may provide a rationale for the combined treatment …
In contrast to our in vitro findings, VEGF serum levels decreased in all patients after 6-9 months of treatment (by an average of 41%) as as …
p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells.
Browne AJ, Göbel A, Thiele S, Hofbauer LC, Rauner M, Rachner TD. Browne AJ, et al. Cell Death Dis. 2016 Feb 25;7(2):e2119. doi: 10.1038/cddis.2016.32. Cell Death Dis. 2016. PMID: 26913608 Free PMC article.
This inhibition was blocked directly by neutralizing DKK-1 using a specific antibody and also indirectly by blocking p38 MAPK. ...These results reveal that p38 MAPK regulates DKK-1 in prostate cancer and may present a potential target in osteolytic prostate cancers. …
This inhibition was blocked directly by neutralizing DKK-1 using a specific antibody and also indirectly by blocking p38 MAPK. ...The …
Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
Göbel A, Thiele S, Browne AJ, Rauner M, Zinna VM, Hofbauer LC, Rachner TD. Göbel A, et al. Cancer Lett. 2016 May 28;375(1):162-171. doi: 10.1016/j.canlet.2016.03.004. Epub 2016 Mar 8. Cancer Lett. 2016. PMID: 26968247
Here, we demonstrate that the treatment of different human breast cancer cell lines (MDA-MB-231, MDA-Bone, and MDA-Met) by combined inhibition of the mevalonate pathway using statins and zoledronic acid at the same time significantly reduces the concentrations required to achieve …
Here, we demonstrate that the treatment of different human breast cancer cell lines (MDA-MB-231, MDA-Bone, and MDA-Met) by combined inhibiti …
Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
Göbel A, Kuhlmann JD, Link T, Wimberger P, Browne AJ, Rauner M, Hofbauer LC, Rachner TD. Göbel A, et al. Breast Cancer Res Treat. 2017 Aug;164(3):737-743. doi: 10.1007/s10549-017-4296-3. Epub 2017 May 19. Breast Cancer Res Treat. 2017. PMID: 28526959
METHODS: Serum DKK-1 and sclerostin levels were measured at primary diagnosis as well as 3-5 days and 12 months after surgery in a cohort of 45 pre- and postmenopausal women with primary estrogen receptor-positive breast cancer treated with adjuvant tamoxifen or aromatase …
METHODS: Serum DKK-1 and sclerostin levels were measured at primary diagnosis as well as 3-5 days and 12 months after surgery in a co …
Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer.
Browne AJ, Kubasch ML, Göbel A, Hadji P, Chen D, Rauner M, Stölzel F, Hofbauer LC, Rachner TD. Browne AJ, et al. Breast Cancer Res. 2017 Aug 9;19(1):92. doi: 10.1186/s13058-017-0885-7. Breast Cancer Res. 2017. PMID: 28793923 Free PMC article.
Everolimus-regulated osteoclastogenesis and osteoblastogenesis were also assessed in vitro before we assessed the bone-protective effect of everolimus in a model where bone loss was induced in ovariectomized (OVX) mice. ...
Everolimus-regulated osteoclastogenesis and osteoblastogenesis were also assessed in vitro before we assessed the bone-protective effect of …
Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients.
Göbel A, Kuhlmann JD, Link T, Wimberger P, Link-Rachner C, Thiele S, Dell'Endice S, Furesi G, Breining D, Rauner M, Hofbauer LC, Rachner TD. Göbel A, et al. J Bone Oncol. 2019 Apr 4;16:100237. doi: 10.1016/j.jbo.2019.100237. eCollection 2019 Jun. J Bone Oncol. 2019. PMID: 31011525 Free PMC article.
Endocrine therapies like tamoxifen and aromatase inhibitors (AI) are a standard therapeutic approach in hormone receptor positive breast cancers. ...METHODS: We measured circulating Sema4D plasma levels at primary diagnosis and in a follow-up sample 12 months after …
Endocrine therapies like tamoxifen and aromatase inhibitors (AI) are a standard therapeutic approach in hormone receptor positive bre …
107 results
Jump to page
Feedback